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Introduction: There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term
clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women. Currently,
research involving trastuzumab at large focuses on the younger population. This study aimed to analyse their biological char-
acteristics and to compare themwith their younger counterparts from a single centre with a long-term clinical follow-up.
Methods: Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable (<5 cm) primary breast cancer
were managed in a dedicated clinic and have complete clinical information available. Of these, 813 patients underwent
primary surgery and 575 had good quality tumour samples available for tissue microarray analysis using indirect immunohis-
tochemistry. Comparison was made with data from a well-characterised younger (<70 years) series (N = 1711) treated
between 1986 and 1998 (before adjuvant trastuzumab became standard) in our institution. Forty ﬁve (7.6%) and 140 (8.2%)
patients from the older and younger series, respectively, had HER2-positive tumours.
Results: HER2 overexpression was seen in 45 (7.6%) older women and 140 (8.2%) in younger patients (P = 0.56). HER2
overexpressing tumours in older women when compared with that in their younger counterparts were associated with low
Ki67 and high bcl2 expression (P < 0.05). Only 26% of the younger patients and none of the older patients received adjuvant
chemotherapy, and no patients at the time received trastuzumab. However, there was no signiﬁcant difference in the
outcome of the two age groups (5-year breast cancer-speciﬁc survival rate: <70 years = 65% versus >70 years = 70%,
P = 0.51).
Conclusion: HER2 overexpressing tumours in older women showed relatively a less aggressive phenotype and did not
show any inferior long-term clinical outcome despite not having received chemotherapy when compared with the younger
patients. The precise role of different adjuvant systemic therapies in this population needs to be delineated.
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introduction
About one-third of breast cancers occur in women over 70 years
of age [1]. With increasing age, there appears to be a change
in biology with more oestrogen receptor (ER) positivity, low
human epidermal growth factor receptor-2 (HER2) positivity
and proliferation [2]. Given the negative correlation between ER
and HER2, a low incidence of HER2-positive tumours can be
expected [3]. However, there is still a considerable proportion of
them who have ER-negative tumours (∼20%) [4]. Therefore,
alongside the small number of ER-positive cases, older women
with HER2-positive disease constitute a signiﬁcant number in
absolute terms.
Overall one-ﬁfth of breast cancers are reported to overexpress
HER2 protein or show gene ampliﬁcation [5, 6]. They are re-
ported to have poor prognosis [5]. However, since the intro-
duction of anti-HER2 therapy, that is trastuzumab in clinical
practice, the outcome has improved [7]. On the other hand, ran-
domised controlled trials were mainly focused on younger
patients, with exclusion or in-appropriate representation of
older women [3]. Thus, due to the limited data reported on the
biology and clinical outcome of the HER2-positive tumours in
older women, this phenotype remains a challenge for clinicians
managing with these patients.
This study aimed to analyse biological characteristics and
long-term clinical outcome of HER2 overexpressing tumours in
older women and to compare with those of younger patients.
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patients andmethods
study patients
Between 1973 and 2010, 1758 older (≥70 years) women with early operable
primary breast cancer (T0–2, N0–1 and M0) were managed in a dedicated
clinic with clinical information available from diagnosis till death/last
follow-up. Eight hundred and thirteen patients underwent primary surgery
(with standard adjuvant therapy as per unit policy based on Nottingham
Prognostic Index (NPI) criteria and ER status, where those with a NPI score
of <3 did not receive any systemic therapy, >3 received adjuvant systemic
therapy including endocrine therapy in patients with ER-positive tumours
and chemotherapy with ER-negative tumours [8]). Of which 238 tumour
blocks were overused or only small number of cells was available which was
not sufﬁcient for analysis, thus 575 good quality formalin-ﬁxed, parafﬁn-
embedded surgical specimens were available for tissue microarray (TMA)
construction.
For comparison, a previously characterised disease stage-matched series
of younger (<70 years) patients (N = 1711) was retrieved from the unit’s
database (Nottingham Tenovus series) [9]. The series comprised clinical and
biological data of younger (<70 years) patients with early operable primary
breast cancer established in 1980s and tumours were prospectively analysed
using immunohistochemistry (IHC) on TMAs, constructed using surgical
specimens (N = 1809). As it was planned at the outset of the project to
compare the older with the younger series, hence variables including bio-
markers collected and the methods for tumour analyses were the same for
both series. All patients were managed following the same clinical guidelines
at the time. None of them received adjuvant trastuzumab, as the younger
series covered a period before trastuzumab was in use as a standard adjuvant
therapy and its use in older patients remains controversial.
Conventional pathological parameters in both groups, including patho-
logical size, grade and axillary stage (according to the number of positive
nodes, 1 = 0 positive, 2 = 1–3 positive, 3 =≥4 positive), were retrieved from
the standard reporting performed at the time of surgery [10].
TMA construction
Construction was made from formalin-ﬁxed, parafﬁn-embedded tumour
sections as previously described [11]. Brieﬂy, 0.6 mm-diameter cores of the
representative part of the tumour blocks were implanted in the recipient
TMA blocks using Beecher’s manual tissue microarrayer (MP06 Beecher
Instruments, Inc., USA).
immunohistochemistry
Indirect IHC was the method used for biomarker analyses. A total of 14
markers were analysed in two age groups by StreptAvidin Biotin Complex
and EnVision methods as described previously [9]. The markers analysed in
the study for comparison include ER, Progesterone receptor (PgR), HER2,
p53, Ki67, Bcl2, Muc1, E-Cadherin, basal and luminal cytokeratins. Details
of antibodies are summarised in Table 1.
scoring
Immunohistochemical staining of the biomarkers was assessed by the per-
centage of cells stained as well as McCarty’s IHC scoring (H-score) (range
0–300) [12]. Cut-offs to deﬁne biomarker positivity were determined by
using the X-tile software (Yale University) [13] based on the percentage of
cells stained (Table 1). For HER2 scoring, the HercepTest scoring system was
used, deﬁned according to the staining of the membrane in 0 = negative (no
membrane staining), 1+ = faint part staining in >10% of cells, 2+ = weak–
moderate membrane staining in >10% of cells and 3+ = strong complete
staining in >10% cells. Those which showed 2+ staining were then analysed
on Chromogen In Situ Hybridisation (CISH) as below. HER2-positive
tumours were deﬁned by IHC 3+ or as gene ampliﬁcation on CISH.
CISH
Slides were dewaxed in xylene and dehydrated in alcohol followed by
washing in wash buffer provided in the Dako, FISH kit. Slides were then pre-
treated in the pre-treatment solution by heating them at 99°C for 10 min fol-
lowed by cooling down at room temperature for 15 min. Slides were soaked
into two baths of wash buffer for 3 min each, then wiped and treated with
pepsin for exactly 6 min at 37°C followed by washing in wash buffer and de-
hydration in alcohol. Ten microlitres of probe mix were applied on dry slides
and sealed with coverslip sealant gel, and incubated for 20 h at 45°C, begin-
ning with 5 min at 80°C using Dako programme hybridiser. Afterwards,
slides were placed in stringent wash buffer at room temperature to allow
gentle separation of the coverslip. Slides were then treated by stringent wash
buffer again for 10 min at 65°C, followed by washing in the wash buffer. Two
hundred microlitres of hydrogen peroxide were applied for 6 min to block
Table 1. A summary of the antibodies source, methods and cut-offs to deﬁne positivity of the markers used to analyse biology of early operable
primary breast cancer in older women
Biomarker Antibody reference Dilution Incubation time (min) Antigen retrieval method Cut-off to deﬁne positivity
ER RM-9101-SP1/NeoMarkers 1:100 45 Citrate buffer 0
PgR PgR 636/Dako 1:200 45 Citrate buffer 0
HER2 Hercep test Kit- Dako Pre-diluted 30 Not required 3+
Ki67 M 7240/Dako 1:100 45 Citrate buffer 10
P53 DO-7/Novocastra 1:100 45 Citrate buffer 5
CK5/6 M7237/Dako 1:100 45 Citrate buffer 10
CK7/8 34779/BioSciences 1:100 45 Citrate buffer 10
CK14 LL002/Vector Laboratories 1:100 45 Citrate buffer 10
CK17 E3/ Vector Laboratories 1:100 45 Citrate buffer 10
CK18 M7010/Dako 1:100 45 Citrate buffer 10
CK19 CM 242A/Biocare Medical 1:100 45 Citrate buffer 10
Bcl2 M0887/Dako 1:100 45 Citrate buffer 10
E-Cadherin M3612/Dako 1:100 45 Citrate buffer 30
Muc1 NCL/Novocastra 1:300 45 Citrate buffer 20
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endogenous peroxidase activity. Slides were then immersed in two baths of
wash buffer. The CISH antibody was applied for 30 min in a humid
chamber, and then washed into two baths of CISH wash buffer. The red
chromogen was applied for 10 min in a humid chamber followed by
washing in wash buffer. The blue chromogen was then applied in the humid
chamber for 10 min followed by washing in wash buffer. The haematoxylin
was applied for 5 min, and the slides were then rinsed with wash buffer and
placed in the wash buffer bath for 5 min. Slides were cleaned with distilled
water and air dried at room temperature, then mounted permanently after
drying.
In terms of CISH scoring, the green and red dots were counted in the
nuclei by using a ﬂuorescent microscope (×100). At least 20 cells were
counted and the ratio of green and red dots was taken. The ratio >2 was con-
sidered positive, whereas <2 was negative.
statistical methods
Data were analysed using the Statistical Package for Social Sciences (SPSS
version 17.0, Chicago, IL, USA). Within the older cohort, the comparisons
were made between HER2-positive and -negative tumours, and then com-
parisons of biology as well as clinical outcome were made with those of the
younger patients. Comparisons were carried out using the χ2 test, and time-
dependent variables were analysed on Kaplan-Meier plots with application
of log-rank and Wilcoxon tests as appropriate. The study intended to
analyse the relationship between biology and clinical outcome. As overall
survival, notably in the older population, would be inﬂuenced by competing
causes of death, it was decided that breast cancer-speciﬁc survival and metas-
tasis-free survival rates were measured and analysed as they were deemed ap-
propriate surrogates for effects of tumour biology and treatments. Data on
co-morbidities were not collected as part of this study. A Multinomial re-
gression model was used to analyse the association of age and tumour char-
acteristics (pathological size, grade and axillary lymph node stage) for the
selection of adjuvant therapy.
ethical approval
The study was approved by the local Institutional Ethical Committee.
results
rate of HER2 positivity
Immunohistochemical score showed that 81.8% (N = 439) were
clearly negative with 0 score, 7.3% (N = 39) were 1+, 3.4%
(N = 18), 165 were 2+ and 7.6% (N = 45) were scored 3+. All 2+
cases (N = 18) were then analysed on CISH and none showed
the ampliﬁed gene. Thus, 7.6% were considered HER2-positive
in our older cohort. From the younger cohort, 140 (8.2%) of
1711 patients had HER2-positive tumours (P = 0.56).
For whole series, median age of the patients was 60 years
(<70 = 53 years and ≥70 = 75 years). Median pathological size of
the tumours was 2.0 cm (<70 = 1.9 cm and ≥70 = 2.3 cm).
treatment pattern
All patients in both groups underwent surgery without any
prior intervention. Adjuvant chemotherapy was received by
28% (N = 36) younger patients and none of the older women
while 26% (N = 12) of older patients and over 42% (N = 57) of
younger patients received adjuvant endocrine therapy. None of
the patient in both groups received adjuvant trastuzumab.
Multinomial logistic regression analysis did not show any
signiﬁcant inﬂuence of patient age and tumour characteristics
on the choice of adjuvant therapy.
age stratiﬁed pattern of HER2 positivity
There appears a gradual decline in HER2 positivity with advan-
cing age (Figure 1A); however, there was a rapid rise in women
<40 years. HER2 positivity in ER-positive and -negative disease
appeared as mirror image, where there was a decline in the ER-
positive group, and a consistent rise followed by a slight decline
in ER-negative tumours (Figure 1B). The decline in HER2 posi-
tivity was pronounced in ER-positive tumours, whereas there
was a slight fall in ER-negative tumours, which still remained
higher.
biology of HER2 overexpressing tumours in older
women
HER2 overexpressing tumours were associated with higher
grade (P < 0.001) and stage (P = 0.009), negative expressions of
ER (P < 0.001), PgR (P < 0.001) and Bcl2 (P < 0.001), and higher
expression of p53 (P < 0.001), CK14 (P = 0.03) and CK17
(P = 0.003) (Table 2).
clinical outcome of HER2 overexpressing tumours
in older women
Older women with overexpressing HER2 showed signiﬁcantly
poorer breast cancer-speciﬁc and metastasis-free survival when
compared with those with HER2-negative tumours (Figure 2A
and B). At median follow-up of 61 months, 90% of HER2-nega-
tive and 78% of HER2-positive patients were still alive without
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Figure 1. (A) Age standardised rate of HER2 overexpression in women
with early operable primary breast cancer. (B) Age standardised rate of
HER2 overexpression in women with early operable primary breast cancer
within ER-positive and -negative tumour groups.
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metastases. None of the biomarkers showed signiﬁcant associ-
ation with the clinical outcome due to very small number of
events in univariate analysis.
biology and clinical outcome of HER2
overexpressing tumours—younger versus older
women
HER2-positive tumours in older women, when compared with
their younger counterparts, showed signiﬁcantly less Ki67
positivity (P < 0.001) and higher positivity for bcl2 (P < 0.001) and
CK14 (P = 0.01) (Table 3). Breast cancer-speciﬁc survival (5-year
rate: <70 years = 65% versus >70 years = 70%, P = 0.51) in the two
groups did not show any signiﬁcant difference (Figure 3A).
discussion
The results of the data showed that HER2 was overexpressed in
∼7% of early operable primary breast cancers in older women.
There appears to be a consistent decline in the expression of
HER2 with advancing age. HER2 positivity showed a positive cor-
relation with higher grade, high stage disease, positive expression
of p53, CK14, CK17 and E-Cadherin, and negative expression of
ER, PgR and Bcl2. HER2 overexpressing tumours showed poor
breast cancer-speciﬁc survival within the older cohort. When
compared with their younger counterparts, they showed less pro-
liferative activity and there appears no signiﬁcant difference in
survival rates in the two age groups, although a considerable pro-
portion of younger patients received chemotherapy. A possible
Table 2. Biological characteristics of HER2 overexpressing tumours
in older women with early operable primary breast cancer
Character HER2 negative HER2 positive P-value
Grade (N = 448)
1 and 2 226 (54.5%) 7 (21.2%) <0.001
3 189 (45.5%) 26 (78.8%)
Stage (N = 333)
1 and 2 279 (90.0%) 16 (69.6%) 0.009
3 31 (10.0%) 7 (30.4%)
ER (N = 518)
Negative 124 (26.0%) 29 (70.7%) <0.001
Positive 353 (74.0%) 12 (29.3%)
PgR (N = 517)
Negative 190 (39.8%) 34 (85.0%) <0.001
Positive 287 (60.2%) 6 (15.0%)
P53 (N = 479)
Negative 278 (62.9%) 13 (35.1%) <0.001
Positive 164 (37.1%) 24 (64.9%)
CK5/6 (N = 468)
Negative 227 (52.8%) 23 (60.5%) 0.22
Positive 203 (47.2%) 15 (39.5%)
CK14 (N = 471)
Negative 335 (77.2%) 23 (62.2%) 0.03
Positive 99 (22.8%) 14 (37.8%)
CK17 (N = 506)
Negative 380 (81.7%) 25 (61.0%) 0.003
Positive 85 (18.3%) 16 (39.0%)
CK7/8 (N = 515)
Negative 15 (3.2%) 0 (0%) 0.302
Positive 461 (96.8%) 39 (100%)
CK18 (N = 498)
Negative 19 (4.2%) 0 (0%) 0.189
Positive 438 (95.8%) 41 (100%)
CK19 (N = 511)
Negative 21 (4.5%) 2 (4.9%) 0.566
Positive 449 (95.5%) 39 (95.1%)
Ki67 (N = 537)
Negative 333 (67.1%) 23 (56.1%) 0.10
Positive 163 (32.9%) 18 (43.9%)
Bcl2 (N = 501)
Negative 65 (14.1%) 14 (35.0%) <0.001
Positive 396 (85.9%) 26 (65.0%)
E-Cadherin (N = 504)
Negative 186 (40.2%) 7 (17.1%) 0.002
Positive 277 (59.8%) 34 (82.9%)
MUC1 (N = 515)
Negative 65 (13.7%) 5 (12.5%) 0.532
Positive 410 (86.3%) 35 (87.5%)
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Figure 2. (A) Time to metastases in older women with early operable
primary breast cancer according to HER2 overexpression—with and without
adjuvant systemic therapy [after median follow-up of 61 (longest 250)
months, 17% (N = 88) developed metastases (HER2 positive = 28.2% versus
HER2 negative = 16.1%)] (log-rank: 4.881). (B) Breast cancer-speciﬁc sur-
vival in older women with early operable primary breast cancer according to
HER2 overexpression—with and without adjuvant systemic therapy [after
median follow-up of 61 (longest 250) months, 16.4% (N = 85) died of breast
cancer (HER2 positive = 28.2% versus HER2 negative = 15.5%)] (log-rank:
7.739).
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explanation is the low expression of Ki67 (a poor prognostic
factor) and high expression of bcl2 (a good prognostic factor)
seen in the older cohort.
HER2-positive tumours comprise ∼20% of all breast cancers
regardless of age; however with advancing age, there appears to
be a decline, as previously reported [14, 15]. In women over 70
years, the rate of HER2 positivity was reported at 5%–15% [3].
The rate of HER2 positivity in our cohort was consistent with
that reported in the literature. The study by Durbecq et al.
showed the same rate in older women as seen in our study. The
study included 14.6% of older women and used IHC, and those
with 2+ score were then conﬁrmed on ﬂuorescent ISH [14].
Other reported studies showed inconsistent methods such as
using only IHC or difference in the deﬁnitions of HER2 positiv-
ity. In our study, there was an interesting pattern showing high
HER2 positivity in a clearly pre-menopausal group (i.e. <40
years) followed by a decline when the majority reached
menopause. This may suggest an association of HER2 status
with menopausal status.
HER2 overexpressing tumours tend to have aggressive biologic-
al characteristics associated with high grade, ER negative expres-
sion and mutant p53 [15]. In addition, our study showed overall
high basal cytokeratins and E-Cadherin and low Bcl2. Little is
known about the biological associations of HER2 overexpressing
tumours with cytokeratins, although the generally high expression
of luminal cytokeratins in older women might have led to the less
obvious distinction across the two age groups.
Regardless of age, HER2 positivity has been reported to have
inferior survival outcome and increased risk of recurrences [16–18].
HER2 has shown a prognostic signiﬁcance in older women similar
to the pattern seen in younger patients, although it is interesting
that there was no signiﬁcant difference in the survival of younger
and older patients with HER2 overexpressing tumours. No patients
in either group received trastuzumab, because the data of the
younger series were collected during 1980–1990s, when trastuzu-
mab was not available, and older women did not receive it due to
the scarcity of robust data showing its use in this age group.
There was a considerable proportion of patients in both
groups who received adjuvant endocrine therapy, while adju-
vant chemotherapy was only given to the younger patients. The
role of adjuvant chemotherapy with or without trastuzumab has
been reported in the literature, whereas that of endocrine
therapy remains controversial [19]. On the other hand, endo-
crine therapy has been observed as a well-tolerated therapy in
older women, where the role of chemotherapy remains in ques-
tion. In the given scenario, the use of trastuzumab is not widely
adopted and the treatment of older women with HER2-positive
tumours remains a challenge. Therefore, it is strongly recom-
mended that the role of trastuzumab as monotherapy as well as
in combination with endocrine therapy in older women with
early operable primary breast cancer should be investigated.
Studies are ongoing to investiage the use of trastuzumab, for
example ‘SafeHer’ [A Safety and Tolerability Study of Assisted-
and Self-Administered Subcutaneous Herceptin (Trastuzumab)
as Adjuvant Therapy in Patients With Early HER2-Positive
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Figure 3. Breast cancer-speciﬁc survival of HER2-positive early operable
primary breast cancer—young versus older women.
Table 3. Biology of HER2 overexpressing tumours—younger (<70
years) versus older (≥70 years) of age
Biomarker <70 years
N (%)
(N = 140)
≥70 years
N (%)
(N = 45)
P-value
Median age (years) 53 75
Pathological size (median, cm) 1.9 2.3 0.16
<3.0 118 (84.3) 37 (82.2)
3.1–5 18 (12.9) 8 (17.7)
>5 4 (2.9) 0 (0)
Grade
≤2 22 (15.7) 7 (18.9) 0.401
3 118 (84.3) 30 (81.1)
Axillary stage
Node negative 73 (52.5) 12 (44.4) 0.27
1–3 nodes positive 43 (30.9) 8 (29.6)
≥4 nodes positive 23 (16.5) 7 (25.9)
ER positive 54 (38.6) 13 (28.9) 0.156
PgR positive 34 (24.3) 8 (18.2) 0.267
Ki67 positive 89 (78.8) 20 (45.5) <0.001
p53 positive 68 (48.6) 25 (58.1) 0.178
E-Cadherin positive 132 (95.0) 40 (88.9) 0.139
Bcl2 positive 15 (28.3) 30 (73.2) <0.001
Muc1 positive 103 (92.0) 41 (95.3) 0.366
CK5/6 positive 25 (18.0) 14 (31.8) 0.04
CK7/8 positive 140 (100) 44 (100) NC
CK14 positive 24 (17.6) 14 (35.0) 0.01
CK17 positive 13 (21.0) 6 (15.4) 0.335
CK18 positive 125 (95.4) 45 (100) 0.165
CK19 positive 133 (95.7) 43 (95.6) 0.624
Treatment pattern
Surgery 140 (100) 45 (100)
Pattern of adjuvant therapy
Radiotherapy 86 (61.4) 9 (20.0)
Endocrine therapy 57 (42) 12 (26.7)
Chemotherapy 36 (28) 0
Trastuzumab 0 0
NC, not computed.
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Breast Cancer], which would be of clinical relevance in older
women.
While the current study is limited by its retrospective nature
and potential bias in terms of treatment selection in older women
(e.g., due to co-morbidites), it possesses strengths in having both
biological information and long-term clinical follow-up data from
a single centre. The key ﬁnding appears to suggest that at least
some older women with HER2-positive tumours may be spared
from chemotherapy, with no adverse impact on survival. This is
partly in contrast to current belief and available literature, and
should be further explored.
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